SteadyMed (STDY) Given Daily News Sentiment Rating of 0.36

News headlines about SteadyMed (NASDAQ:STDY) have been trending positive recently, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. SteadyMed earned a news sentiment score of 0.36 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.6615610343791 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Several equities analysts have weighed in on the stock. Zacks Investment Research upgraded shares of SteadyMed from a “hold” rating to a “strong-buy” rating and set a $3.25 target price on the stock in a report on Thursday, April 12th. JMP Securities reiterated a “buy” rating on shares of SteadyMed in a report on Wednesday, January 10th.

NASDAQ:STDY traded up $0.19 on Thursday, hitting $3.19. The stock had a trading volume of 6,989 shares, compared to its average volume of 15,143. The firm has a market capitalization of $82.38, a price-to-earnings ratio of -7.42 and a beta of 0.53. SteadyMed has a 1-year low of $2.80 and a 1-year high of $7.50.

WARNING: “SteadyMed (STDY) Given Daily News Sentiment Rating of 0.36” was originally published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/3371162/steadymed-stdy-given-daily-news-sentiment-rating-of-0-36.html.

About SteadyMed

SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical company that focuses on the development and commercialization of drug product candidates for the treatment of orphan and other diseases with unmet parenteral delivery needs. The company's product candidates are enabled by its proprietary PatchPump, a discreet, pre-filled, water-resistant, and disposable parenteral drug administration technology.

Insider Buying and Selling by Quarter for SteadyMed (NASDAQ:STDY)

Receive News & Ratings for SteadyMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SteadyMed and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

TopBuild  Hits New 52-Week High and Low at $84.52
TopBuild Hits New 52-Week High and Low at $84.52
Nu Skin Enterprises  Sets New 52-Week High and Low at $81.72
Nu Skin Enterprises Sets New 52-Week High and Low at $81.72
Jaguar Health  Shares Gap Down to $0.14
Jaguar Health Shares Gap Down to $0.14
ValuEngine Downgrades LG Display  to Strong Sell
ValuEngine Downgrades LG Display to Strong Sell
GTX  Upgraded at ValuEngine
GTX Upgraded at ValuEngine
Community Health Systems  Upgraded at ValuEngine
Community Health Systems Upgraded at ValuEngine


© 2006-2018 Ticker Report. Google+.